申请人:Vertex Pharmaceuticals Incorporated
公开号:EP3798214A1
公开(公告)日:2021-03-31
The present invention features a compound of formula I:
or a pharmaceutically acceptable salt thereof, where R1, R2, R3, W, X, Y, Z, n, o, p, and q are defined herein, for the treatment of CFTR mediated diseases, such as cystic fibrosis. The present invention also features pharmaceutical compositions, method of treating, and kits thereof.
本发明的特征是一种式 I 的化合物:
或其药学上可接受的盐,其中 R1、R2、R3、W、X、Y、Z、n、o、p 和 q 在本文中定义,用于治疗 CFTR 介导的疾病,如囊性纤维化。本发明还包括药物组合物、治疗方法及其试剂盒。